AstraZeneca PLC filings document the disclosures of a foreign private issuer focused on prescription medicines across oncology, rare diseases, cardiovascular, renal and metabolism, respiratory, and immunology. The company’s Form 6-K reports include quarterly operating results, product sales, alliance and collaboration revenue, EPS measures, and management commentary on medicine performance and pipeline progress.
Other filings record FDA advisory-committee and approval updates for medicines such as TRUQAP, BREZTRI, SAPHNELO, camizestrant, and ULTOMIRIS; Phase III trial disclosures; licensing arrangements; Board changes; total voting rights; and admission of additional ordinary shares. These documents also provide capital-structure and governance information relevant to AstraZeneca’s UK issuer framework and SEC foreign-issuer reporting obligations.
AstraZeneca PLC filed a foreign issuer report showing that an investor group linked to The Capital Group Companies, Inc. has crossed a key ownership threshold in the company.
According to the notification, Capital Group now holds 77,684,561 voting rights in AstraZeneca, equal to 5.009701% of the company’s voting rights, up from 4.997854%. This stake is held entirely through shares, with 62,998,778 voting rights in common stock (representing 4.062648%) and 14,685,783 voting rights via depository receipts (representing 0.947053%). No voting rights are held through derivative or other financial instruments, indicating a straightforward shareholding structure at this time.
AstraZeneca PLC furnished a Form 6-K reporting a notification of major holdings showing that The Capital Group Companies, Inc. and its affiliated investment managers crossed the 5% ownership threshold on 20-Aug-2025. The filing shows a resulting position of 77,500,852 shares, representing 5.009591% of voting rights, plus 14,685,540 depository receipts held indirectly (reported as 0.947037% indirect voting rights).
The disclosure explains the asset managers manage these shares on behalf of discretionary client accounts and that neither CGC nor its affiliates hold the shares for their own account. The Form 6-K is a routine, regulatory notification of significant institutional ownership rather than a corporate action by AstraZeneca.
AstraZeneca PLC reported a notification that its Executive Director and Chief Financial Officer, Aradhana Sarin, executed a sale of the company’s ordinary shares on 14 August 2025. The filing, provided on 18 August 2025, discloses a transaction price of £115.117 per share. The announcement follows EU Market Abuse Regulation reporting requirements as incorporated into UK law. The notice does not clearly state the number of shares sold in the visible text, so the total proceeds and percentage ownership change are not determinable from this filing alone.
AstraZeneca PLC received a TR-1 notification showing The Capital Group Companies, Inc. and its affiliates reported a combined holding of 77,682,857 ordinary shares, representing 4.984560% of voting rights as of 14-Aug-2025. Of that total, 14,351,342 are held as depository receipts (ISIN US0463531089), representing 0.925485% of voting rights. The filing clarifies these shares are owned by client accounts under discretionary management across Capital Group entities, not held for the parent companies' own accounts. The notification supplies the chain of controlled undertakings through which the holdings are managed and is signed by AstraZeneca's Company Secretary on 15 August 2025.
AstraZeneca received a TR-1 notification showing The Capital Group Companies, Inc. and its investment management affiliates crossed the 5% voting threshold in AstraZeneca ordinary shares on 11-Aug-2025. The notification reports a resulting total holding of 5.000629% of voting rights, represented by 77,294,699 underlying voting rights and 14,394,421 depository receipts (ISIN US0463531089) accounting for 0.928264% of voting rights. The filing discloses the full chain of controlled undertakings through which the holdings are held and explains these shares are owned by client accounts under discretionary management by Capital Group entities rather than for Capital Group's own account.
H1 2025 results: Total revenue rose 11% CER to $28.0 bn, led by Oncology (+16%) and BioPharmaceuticals. Product Sales were $26.7 bn (+10%), Alliance Revenue $1.3 bn (+38%). Core EPS reached $4.66 (+17%) and reported EPS $3.46 (+32%) as core operating profit advanced 13%.
Q2 2025: Revenue grew 11% CER to $14.5 bn; core EPS $2.17 (+12%). Gross margin 83%; reported operating margin 24% (core 32%). Key brands outperformed: Tagrisso $3.5 bn (+10%), Imfinzi $2.7 bn (+21%), Enhertu $1.3 bn (+38%) while Soliris (-30%) and Brilinta (-21%) declined.
Capital allocation & strategy: Interim dividend increased 3% to $1.03. AZN acquired cell-therapy firm EsoBiotec for up to $1 bn, signed a $110 m upfront AI-drug-discovery deal with CSPC (milestones up to $5.2 bn) and announced a $50 bn US manufacturing/R&D investment, including a new Virginia drug-substance plant.
R&D momentum: 12 positive Phase III readouts (e.g., baxdrostat BaxHTN, Tagrisso FLAURA2) and 19 approvals. Pipeline breadth reinforced by oncology, CVRM and rare-disease advances.
Guidance reaffirmed: 2025 total revenue to grow high-single-digits and core EPS low-double-digits (CER); FX now seen broadly neutral. Core tax rate 18-22%.